Home Page >> Lawsuits Filed >> Lawsuit: Neurontin (Gabapentin)

Pfizer Faces Class Action over Neurontin and Alleged Risk for Suicidal Behavior

London, ON: In reasons released yesterday afternoon, Justice Paul Perell of the Ontario Superior Court of Justice ordered that an action relating to the drug Neurontin (gabapentin) be certified as a national class excluding residents of Quebec. The action alleges that use of Neurontin, a prescription anticonvulsant that is commonly prescribed for off-label uses, results in an increased risk of experiencing suicidal behaviour.

Among the issues the court approved for determination are whether Neurontin is ineffective and/or defective or unfit for the purpose for which it was intended and sold, and whether Pfizer breached a duty to warn class members or materially misrepresented any of the risks of harm from using Neurontin. Another issue approved for determination is whether the class can elect to require Pfizer to account for all or part of the gross revenue or net income received from the sale of Neurontin.

It is too early at this stage to quantify the claims of class members, but it is anticipated that the amount will be significant.

Neurontin Class Action Legal Help

If you or a loved one has suffered adverse health events in this case, please click the link below and your complaint will be sent to a lawyer who may evaluate your claim at no cost or obligation.

Last updated on Feb-19-10